Clinical trial
A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood…
NCT00067730 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00067730 |
|---|---|
| Title | A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation |
| Official title | A Safety Evaluation of Xigris Drotrecogin Alfa Activated in Hematopoietic Stem Cell Transplant Patients With Severe Sepsis |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Sepsis, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Infection |
| Intervention type | Drug |
| Interventions | Drotrecogin Alfa (activated) |
| Enrollment | 7 |
| Start date | Mar 1, 2003 |
| Completion | Oct 1, 2003 |
| First posted | Aug 27, 2003 |
| Last update posted | Dec 7, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: